Recent blog posts
Functional dyspepsia Indication Strategy Report 2026: 5-HT4 receptor, Trials and Deals
Latest Hotspot
8 min read
Functional dyspepsia Indication Strategy Report 2026: 5-HT4 receptor, Trials and Deals
23 July 2026
2026 Functional dyspepsia strategy: epidemiology, 5-HT4 receptor biology, clinical competition, recent deals, unmet need and market attractiveness.
Read →
Porphyria cutanea tarda Indication Strategy Report 2026: UROD, Trials and Deals
Latest Hotspot
8 min read
Porphyria cutanea tarda Indication Strategy Report 2026: UROD, Trials and Deals
23 July 2026
2026 Porphyria cutanea tarda strategy: epidemiology, UROD biology, clinical competition, recent deals, unmet need and market attractiveness.
Read →
Grover disease Indication Strategy Report 2026: TRPV3, Trials and Deals
Latest Hotspot
8 min read
Grover disease Indication Strategy Report 2026: TRPV3, Trials and Deals
23 July 2026
2026 Grover disease strategy: epidemiology, TRPV3 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Read →
Wells syndrome Indication Strategy Report 2026: IL-5, Trials and Deals
Latest Hotspot
8 min read
Wells syndrome Indication Strategy Report 2026: IL-5, Trials and Deals
23 July 2026
2026 Wells syndrome strategy: epidemiology, IL-5 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Read →
Eosinophilic fasciitis Indication Strategy Report 2026: IL-5, Trials and Deals
Latest Hotspot
8 min read
Eosinophilic fasciitis Indication Strategy Report 2026: IL-5, Trials and Deals
23 July 2026
2026 Eosinophilic fasciitis strategy: epidemiology, IL-5 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Read →
Morphea Indication Strategy Report 2026: TGF-beta, Trials and Deals
Latest Hotspot
8 min read
Morphea Indication Strategy Report 2026: TGF-beta, Trials and Deals
23 July 2026
2026 Morphea strategy: epidemiology, TGF-beta biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Read →
Discoid lupus erythematosus Indication Strategy Report 2026: TYK2, Trials and Deals
Latest Hotspot
8 min read
Discoid lupus erythematosus Indication Strategy Report 2026: TYK2, Trials and Deals
23 July 2026
2026 Discoid lupus erythematosus strategy: epidemiology, TYK2 biology, clinical competition, recent deals, unmet need and market attractiveness.
Read →
Cutaneous lupus erythematosus Indication Strategy Report 2026: IFNAR1, Trials and Deals
Latest Hotspot
8 min read
Cutaneous lupus erythematosus Indication Strategy Report 2026: IFNAR1, Trials and Deals
23 July 2026
2026 Cutaneous lupus erythematosus strategy: epidemiology, IFNAR1 biology, clinical competition, recent deals, unmet need and market attractiveness.
Read →
Autoimmune pancreatitis Indication Strategy Report 2026: CD20, Trials and Deals
Latest Hotspot
8 min read
Autoimmune pancreatitis Indication Strategy Report 2026: CD20, Trials and Deals
23 July 2026
2026 Autoimmune pancreatitis strategy: epidemiology, CD20 biology, clinical competition, recent deals, unmet need and market attractiveness.
Read →
Autoimmune gastritis Indication Strategy Report 2026: BAFF, Trials and Deals
Latest Hotspot
8 min read
Autoimmune gastritis Indication Strategy Report 2026: BAFF, Trials and Deals
23 July 2026
2026 Autoimmune gastritis strategy: epidemiology, BAFF biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Read →
Pernicious anemia Indication Strategy Report 2026: BAFF, Trials and Deals
Latest Hotspot
8 min read
Pernicious anemia Indication Strategy Report 2026: BAFF, Trials and Deals
23 July 2026
2026 Pernicious anemia strategy: epidemiology, BAFF biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Read →
Autoimmune neutropenia Indication Strategy Report 2026: FcRn, Trials and Deals
Latest Hotspot
8 min read
Autoimmune neutropenia Indication Strategy Report 2026: FcRn, Trials and Deals
23 July 2026
2026 Autoimmune neutropenia strategy: epidemiology, FcRn biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Read →